Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV mRNA Investigational Vaccine in Healthy Participants 18-45 Years of Age
NCT06573281Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial of RSV vaccine in respiratory syncytial virus infection (RSV) (7 arms), sponsored by GSK. Primary endpoints: Number of participants reporting solicited administration site events, Number of participants reporting solicited systemic events and 5 more. Started Sep 2024; status: completed.
02
Drugs
RSV vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06573281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573281.